Antineoplastic Agents

All Drugs and Chemicals

Nivolumab

Antineoplastic Agents, Immunological

Immune Checkpoint Inhibitors

Study treatment consists of nivolumab 3mg/kg, and will be repeated every 2 weeks.

Kyong Hwa Park, MD, PhD

Kyong Hwa Park, MD, phD

A Phase II Study of Nivolumab in Patients with Genetic alterations in DNA Damage repair and response Who Progressed after Standard treatment for Metastatic Solid Cancers

All the patients will be included in the final analysis, with a total of 48 patients to be enrolled.

Treatment will occur until disease progression, unacceptable toxicity or patient withdrawal.

Study treatment consists of nivolumab 3mg/kg, and will be repeated every 2 weeks.

Response evaluation will be performed every 6 weeks (+/- 1 week window period is allowed).

A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers

the percentage of patients experiencing confirmed complete response (CR) and partial response (PR) assessed by RECIST criteria v.1.1

the time from study entry until the first observation of disease progression

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers	NCT04761744	DDR Gene Mutati... Metastatic Soli...	Nivolumab	20 Years -	Korean Cancer Study Group
A Phase II Study of Nivolumab in Patients With Genetic Alterations in DNA Damage Repair and Response Who Progressed After Standard Treatment for Metastatic Solid Cancers	NCT04761744	DDR Gene Mutati... Metastatic Soli...	Nivolumab	20 Years -	Korean Cancer Study Group

Spots Global Cancer Trial Database for ddr gene mutation